# GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

> **NCT05191784** · PHASE2 · UNKNOWN · sponsor: **Genexine, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **DRUG:** GX-I7
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05191784
- **Lead sponsor:** Genexine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-26
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05191784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05191784, "GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05191784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*